Australia markets close in 1 minute

ABBV Jan 2025 155.000 call

OPR - OPR Delayed price. Currency in USD
Add to watchlist
10.57+0.16 (+1.54%)
As of 12:32PM EST. Market open.
Full screen
Previous close10.41
Open10.00
Bid10.45
Ask10.95
Strike155.00
Expiry date2025-01-17
Day's range10.00 - 10.57
Contract rangeN/A
Volume10
Open interest2.73k
  • Yahoo Finance Video

    FTC warns pharma companies on excessive drug patenting

    The Federal Trade Commission (FTC) issued warning letters to several pharmaceutical companies, including AbbVie (ABBV) AstraZeneca (AZN), and Teva (TEVA), over excessive patenting of medications as Medicare negotiates drug costs with the pharma industry. Yahoo Finance Health Reporter Anjalee Khemlani explains the Biden administration's ideas to license patents to lower drug costs for patients. For more expert insight and the latest market action, click here to watch this full episode of Yahoo Finance Live.

  • Yahoo Finance Video

    AbbVie acquiring Cerevel Therapeutics in $8.7B deal

    AbbVie (ABBV) announced it is acquiring neuroscience drug developer Cerevel Therapeutics (CERE) for $45.00 per share, putting the deal value at about $8.7 billion. AbbVie Chairman and CEO Richard Gonzalez said in the announcement that the combined portfolios will present a "significant growth opportunity well into the next decade." The deal comes about a week after AbbVie announced it was acquiring cancer drugmaker ImmunoGen (IMGN) for just over $10 billion. Yahoo Finance Healthcare Reporter Anjalee Khemlani breaks down the deal.  For more expert insight and the latest market action, click here to watch this full episode of Yahoo Finance Live.

  • Zacks

    Top Stock Reports for AbbVie, NIKE & BHP

    Today's Research Daily features new research reports on 16 major stocks, including AbbVie Inc. (ABBV), NIKE, Inc. (NKE) and BHP Group Ltd. (BHP).